Faruqi & Faruqi, LLP Announces Investigation of Gen-Probe Inc. (GPRO)
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Gen-Probe Inc. (“Gen-Probe” or the “Company”) (NASDAQ: GPRO) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Hologic Inc. (NASDAQ: HOLX) in an all-cash transaction valued at approximately $3.7 billion, including Gen-Probe’s net debt. Under the terms of the proposed transaction, Gen-Probe shareholders will receive $82.75 in cash per each share of Gen-Probe common stock they own.
Whether Gen-Probe’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether the proposed transaction undervalues Gen-Probe’s shares and by how much this proposed transaction undervalues the Company to the detriment of Gen-Probe’s shareholders are the key focus of this investigation.
Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.
* The submission of this form does not create an attorney-client relationship.
Juan E. Monteverde
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.